By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Merrimack Pharmaceuticals this week said that it has raised $77 million in a Series G private financing.

The firm, which is developing cancer therapeutics and companion molecular diagnostics, said that it would use the funds to support its pipeline of cancer therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.